Fullerton Catherine A, Busch Alisa B, Normand Sharon-Lise T, McGuire Thomas G, Epstein Arnold M
Department of Health Care Policy, Harvard Medical School, Boston, MA 02115, USA.
Arch Gen Psychiatry. 2011 Dec;68(12):1218-26. doi: 10.1001/archgenpsychiatry.2011.146.
During the past decade, the introduction of generic versions of newer antidepressants and the release of Food and Drug Administration warnings regarding suicidality in children, adolescents, and young adults may have had an effect on cost and quality of depression treatment.
To examine longitudinal trends in health service utilization, spending, and quality of care for depression.
Observational trend study.
Florida Medicaid enrollees, between July 1, 1996, and June 30, 2006. Patients Annual cohorts aged 18 to 64 years diagnosed as having depression.
Mental health care spending (adjusted for inflation and case mix), as well as its components, including inpatient, outpatient, and medication expenditures. Quality-of-care measures included medication adherence, psychotherapy, and follow-up visits.
Mental health care spending increased from a mean of $2802 per enrollee to $3610 during this period (29% increase). This increase occurred despite a mean decrease in inpatient spending from $641 per enrollee to $373 and was driven primarily by an increase in pharmacotherapy spending (up 110%), the bulk of which was due to spending on antipsychotics (949% increase). The percentage of enrollees with depression who were hospitalized decreased from 9.1% to 5.1%, and the percentage who received psychotherapy decreased from 56.6% to 37.5%. Antidepressant use increased from 80.6% to 86.8%, anxiety medication use was unchanged at 62.7% and 64.4%, and antipsychotic use increased from 25.9% to 41.9%. Changes in quality of care were mixed, with antidepressant use improving slightly, psychotherapy utilization fluctuating, and follow-up visits decreasing.
During a 10-year period, spending for Medicaid enrollees with depression increased substantially, with minimal improvements in quality of care. Antipsychotic use contributed significantly to the increase in spending, while contributing little to traditional measures of quality of care.
在过去十年中,新型抗抑郁药通用版本的推出以及美国食品药品监督管理局发布的关于儿童、青少年和青年自杀倾向的警告,可能对抑郁症治疗的成本和质量产生了影响。
研究抑郁症医疗服务利用、支出和护理质量的纵向趋势。
观察性趋势研究。
1996年7月1日至2006年6月30日期间的佛罗里达州医疗补助计划参保者。患者为年龄在18至64岁之间被诊断患有抑郁症的年度队列。
心理健康护理支出(根据通货膨胀和病例组合进行调整)及其组成部分,包括住院、门诊和药物支出。护理质量指标包括药物依从性、心理治疗和随访就诊。
在此期间,心理健康护理支出从每位参保者平均2802美元增加到3610美元(增长29%)。尽管住院支出从每位参保者平均641美元降至373美元,但这一增长仍然出现,主要是由药物治疗支出的增加推动的(增长110%),其中大部分归因于抗精神病药物的支出(增长949%)。患有抑郁症的参保者住院率从9.1%降至5.1%,接受心理治疗的比例从56.6%降至37.5%。抗抑郁药的使用从80.6%增加到86.8%,抗焦虑药物的使用保持在62.7%和64.4%不变,抗精神病药物的使用从25.9%增加到41.9%。护理质量的变化喜忧参半,抗抑郁药的使用略有改善,心理治疗的利用率波动,随访就诊减少。
在10年期间,患有抑郁症的医疗补助计划参保者的支出大幅增加,而护理质量的改善微乎其微。抗精神病药物的使用对支出的增加有显著贡献,而对传统护理质量指标的贡献很小。